Long-Term Immunogenicity and Protection of a rHVT-H9/Y280 Vaccine Against H9N2 Avian Influenza Virus in Commercial Layers with High Maternal Antibodies
Animals · 13.01.2026 · 16 (2) · 242
DOI: 10.3390/ani16020242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animals, online erschienen am 13.01.2026. Verfasst von Sang-Won Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Avian Diseases, College of Veterinary Medicine and Center for Avian Disease, Jeonbuk National University, Iksan 54596, Republic of Kore…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries, research funds for newly appointed professors of Jeonbuk National University, selection of research-oriented professor of Jeonbuk National University.
Abstract (Originalsprache)
The endemicity of H9N2 avian influenza viruses (AIVs), particularly the Y280 lineage, poses persistent challenges to the poultry industry due to the limitations of inactivated vaccines, such as interference by maternally derived antibodies (MDAs) and incomplete suppression of viral replication. This study evaluated the immunogenicity and protective efficacy of a novel recombinant turkey herpesvirus vaccine expressing the hemagglutinin gene of H9N2/Y280 (rHVT-H9/Y280) in commercial Hy-Line Brown layers with high-MDA backgrounds. In a comparative challenge study, the rHVT-H9/Y280 vaccine induced complete protection against a homologous Y280 strain challenge at 4 weeks of age, whereas commercial inactivated vaccines failed to completely block replication, showing virus isolation rates of 16.7–25%. Long-term serological monitoring demonstrated that the rHVT-H9/Y280 vaccine elicited a robust humoral response characterized by persistent maintenance of high HI titers (>8.0 log2) up to 39 weeks post-vaccination. These findings confirm that rHVT-H9/Y280 effectively overcomes MDA interference and provides protection by inhibition of viral replication in layer chickens, making it a promising candidate for the effective control of H9N2 AIV in endemic regions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Avian Diseases, College of Veterinary Medicine and Center for Avian Disease, Jeonbuk National University, Iksan 54596, Republic of Korea.
- Bio Disease Control (BIOD) Co., Ltd., Iksan 54596, Republic of Korea.
ORCID-Profile: Jong-Yeol Park, Kai-Qiong Zheng, Cheng-Dong Yu
Förderung
- Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries
- research funds for newly appointed professors of Jeonbuk National University
- selection of research-oriented professor of Jeonbuk National University
- Ministry of Agriculture, Food and Rural Affairs
Zitieren
APA
Kim, S. W., Park, J. Y., Son, J. E., Zheng, K. Q., Yu, C. D., Kim, K. W., Jeon, W. B., Choi, Y. R., Jang, H. K., Wei, B., & Kang, M. (2026). Long-Term Immunogenicity and Protection of a rHVT-H9/Y280 Vaccine Against H9N2 Avian Influenza Virus in Commercial Layers with High Maternal Antibodies. Animals, 16(2), 242. https://doi.org/10.3390/ani16020242
Vancouver
Kim SW, Park JY, Son JE, Zheng KQ, Yu CD, Kim KW, et al. Long-Term Immunogenicity and Protection of a rHVT-H9/Y280 Vaccine Against H9N2 Avian Influenza Virus in Commercial Layers with High Maternal Antibodies. Animals. 2026;16(2):242. doi:10.3390/ani16020242
BibTeX
@article{Kim2026,
author = {Kim, Sang-Won and Park, Jong-Yeol and Son, Ji-Eun and Zheng, Kai-Qiong and Yu, Cheng-Dong and Kim, Ki-Woong and Jeon, Won-Bin and Choi, Yu-Ri and Jang, Hyung-Kwan and Wei, Bai and Kang, Min},
title = {Long-Term Immunogenicity and Protection of a rHVT-H9/Y280 Vaccine Against H9N2 Avian Influenza Virus in Commercial Layers with High Maternal Antibodies},
journal = {Animals},
year = {2026},
volume = {16},
number = {2},
pages = {242},
doi = {10.3390/ani16020242}
}
EUVIMED